"B7-H1 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitory B7 antigen that contains V-type and C2 type immunoglobulin domains. It has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 PROTEIN and provides negative signals that control and inhibit T-cell responses. It is found at higher than normal levels on tumor cells, suggesting its potential role in TUMOR IMMUNE EVASION.
| Descriptor ID |
D060890
|
| MeSH Number(s) |
D12.776.467.150.300 D12.776.543.095.300 D23.050.301.285.400 D23.529.168.300
|
| Concept/Terms |
B7-H1 Antigen- B7-H1 Antigen
- Antigen, B7-H1
- B7 H1 Antigen
- Programmed Cell Death 1 Ligand 1
- B7-H1 Immune Costimulatory Protein
- B7 H1 Immune Costimulatory Protein
- PD-L1 Costimulatory Protein
- Costimulatory Protein, PD-L1
- PD L1 Costimulatory Protein
- Programmed Cell Death 1 Ligand 1 Protein
- CD274 Antigen
- Antigen, CD274
- Antigens, CD274
- CD274 Antigens
- B7H1 Immune Costimulatory Protein
|
Below are MeSH descriptors whose meaning is more general than "B7-H1 Antigen".
Below are MeSH descriptors whose meaning is more specific than "B7-H1 Antigen".
This graph shows the total number of publications written about "B7-H1 Antigen" by people in this website by year, and whether "B7-H1 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2014 | 3 | 0 | 3 |
| 2015 | 2 | 0 | 2 |
| 2017 | 2 | 4 | 6 |
| 2018 | 5 | 3 | 8 |
| 2019 | 5 | 3 | 8 |
| 2020 | 4 | 5 | 9 |
| 2021 | 3 | 3 | 6 |
| 2022 | 1 | 7 | 8 |
| 2023 | 4 | 6 | 10 |
| 2024 | 0 | 4 | 4 |
| 2025 | 2 | 4 | 6 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "B7-H1 Antigen" by people in Profiles.
-
Immune Checkpoint Inhibitor-Induced Diabetes Across National Cancer Institute Trials That Included PD-1 or PD-L1 Agents. JAMA Oncol. 2026 Feb 01; 12(2):194-199.
-
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature. 2025 Nov; 647(8089):488-497.
-
Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial. Nat Commun. 2025 Sep 29; 16(1):8567.
-
PD-L1 and Ki-67 Expression Before and After Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. Int J Urol. 2025 Sep; 32(9):1195-1202.
-
The role of PD-1/PD-L1 in overshooting osteoclastogenesis in periprosthetic joint infections. Commun Biol. 2025 May 22; 8(1):786.
-
A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function. Cancer Res Commun. 2025 03 01; 5(3):527-548.
-
Sigma1 inhibitor suppression of adaptive immune resistance mechanisms mediated by cancer cell derived extracellular vesicles. Cancer Biol Ther. 2025 Dec; 26(1):2455722.
-
IRE1a silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer. Cell. 2024 Dec 12; 187(25):7248-7266.e34.
-
Soluble mesothelin-related peptide as a prognosticator in pleural mesothelioma patients receiving checkpoint immunotherapy. J Thorac Cardiovasc Surg. 2025 04; 169(4):1082-1095.e4.
-
STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-?-induced Apoptosis in Urothelial Cancer. Anticancer Res. 2024 May; 44(5):1925-1930.